Latanoprost is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. 

• Open angle glaucoma
• Ocular hypertension

Glaucoma

Elevated IOP (Intra Occular Pressure)

• Recommended therapy is one eye drop in the affected eye(s) once daily. Optimal effect is obtained if Latanoprost eye drops is administered in the evening.
• The dosage of Latanoprost eye drops should not exceed once daily since it has been shown that more frequent administration decreases the intraocular pressure lowering effect.
• If one dose is missed, treatment should continue with the next dose as normal

Latanoprost may cause the following side effects-

• ocular hyperemia 
• decreased visual acuity
• eye discomfort
• foreign body sensation
• pain
• pruritus
• abnormal vision
• blepharitis
• blurred vision
• cataract
• conjunctivitis
• corneal staining
• dry eye
• iris discoloration
• keratitis
• lid margin crusting
• ocular inflammation
• photophobia
• subconjunctival hemorrhage and tearing

Watery Eye

Ocular burning/ Eye burning

Eye Irritation

Dry Eye

• Pigmentation: Pigmentation of the iris, periorbital tissue (eyelid) and eyelashes can occur. Iris pigmentation likely to be permanent. 
• Eyelash Changes: Gradual change to eyelashes including increased length, thickness and number of lashes. It is usually reversible. 
• Latanoprost should be used with caution in patients with active intraocular inflammation (e.g., uveitis) because the inflammation may be exacerbated. 
• Macular edema, including cystoid macular edema, has been reported during treatment with Latanoprost ophthalmic 
• Latanoprost has not been evaluated for the treatment of angle-closure, inflammatory or neovascular glaucoma. 
• Contact lenses should be removed prior to instillation of Latanoprost and may be reinserted 15 minutes following its administration. 
• Bacterial keratitis has been linked to the use of multiple-dose containers of topical ophthalmic products. These containers had been contaminated inadvertently by patients, the majority of whom had a concurrent corneal disease or a disruption of the ocular epithelial surface.